Denny Dones's Uploads

515 Uploads

Roche’s Glofitamab
Roche’s Glofitamab
  • 17 vues
Braftovi shows a higher response rate in a triplet combination after adding Opdi
Braftovi shows a higher response rate in a triplet combination after adding Opdi
  • 14 vues
Closely watched Janssen and Legend Biotech's CAR-T cell therapy
Closely watched Janssen and Legend Biotech's CAR-T cell therapy
  • 18 vues
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/R f
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/R f
  • 42 vues
Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic
Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic
  • 10 vues
Enhertu carving out a new space for itself in HER2 low patients
Enhertu carving out a new space for itself in HER2 low patients
  • 23 vues
ASCO 2022 Conference
ASCO 2022 Conference
  • 15 vues
Newly Launched First in Class LAG-3 Combination Drug Opdualag
Newly Launched First in Class LAG-3 Combination Drug Opdualag
  • 41 vues
Encouraging results of nivolumab bevacizumab FOLFOXIRI
Encouraging results of nivolumab bevacizumab FOLFOXIRI
  • 14 vues
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise
  • 16 vues
Vasomotor symptoms (Hot flashes/Night sweats) Infographics
Vasomotor symptoms (Hot flashes/Night sweats) Infographics
  • 11 vues
Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-
Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-
  • 17 vues
Primary Hyperoxaluria Market Insight, Epidemiology And Market Forecast - 2032
Primary Hyperoxaluria Market Insight, Epidemiology And Market Forecast - 2032
  • 8 vues
The PROs Further Support Durvalumab Chemo in Becoming The New Standard of Care
The PROs Further Support Durvalumab Chemo in Becoming The New Standard of Care
  • 11 vues
Takeda’s Flagship Product Panitumumab (PAN) mFOLFOX6 Versus bevacizumab (BEV)
Takeda’s Flagship Product Panitumumab (PAN) mFOLFOX6 Versus bevacizumab (BEV)
  • 8 vues
Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Sta
Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Sta
  • 15 vues
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market
  • 14 vues
With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For
With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For
  • 11 vues
Chronic Lower Back Pain Infographic Market Infographic
Chronic Lower Back Pain Infographic Market Infographic
  • 23 vues
Is there enough opportunity in the competitive therapeutic landscape of Multiple
Is there enough opportunity in the competitive therapeutic landscape of Multiple
  • 16 vues
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses In
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses In
  • 22 vues
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC
  • 10 vues
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic H
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic H
  • 14 vues
Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR
Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR
  • 6 vues
Nasal Polyposis - Market Insight, Epidemiology And Market Forecast - 2032
Nasal Polyposis - Market Insight, Epidemiology And Market Forecast - 2032
  • 9 vues
Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma
Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma
  • 8 vues
What is the Multiple Sclerosis?
What is the Multiple Sclerosis?
  • 9 vues
Newly Diagnosed Glioblastoma
Newly Diagnosed Glioblastoma
  • 9 vues
With the emergence of Next-generation SERDs, Sanofi might hit the mark
With the emergence of Next-generation SERDs, Sanofi might hit the mark
  • 9 vues
Elranatamab exhibits a 60.6% ORR and a tolerable safety profile
Elranatamab exhibits a 60.6% ORR and a tolerable safety profile
  • 16 vues
What is the Common Warts?
What is the Common Warts?
  • 5 vues
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expressed i
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expressed i
  • 14 vues
Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC Trial
Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC Trial
  • 17 vues
Is GSK's Jemperli giving us reason to believe that cancer can be beaten? It's in
Is GSK's Jemperli giving us reason to believe that cancer can be beaten? It's in
  • 8 vues
CEL-SCI Corporation Presents First-of-its-Kind Results For Lower-Risk Advanced P
CEL-SCI Corporation Presents First-of-its-Kind Results For Lower-Risk Advanced P
  • 5 vues
ASCO Conference 2022- Breast Cancer
ASCO Conference 2022- Breast Cancer
  • 81 vues
ASCO 2022 Conference
ASCO 2022 Conference
  • 82 vues
Genmab/Abbvie's Epcoritamab Achieves a 100% Response Rate In Patients With R/R F
Genmab/Abbvie's Epcoritamab Achieves a 100% Response Rate In Patients With R/R F
  • 23 vues
ASCO 2022 Conference
ASCO 2022 Conference
  • 15 vues
Neurofibromatosis Newsletter
Neurofibromatosis Newsletter
  • 7 vues